Erasca (Nasdaq: ERAS) announced that its Board approved inducement equity awards in connection with the appointment of Charles S. Fuchs, M.D., M.P.H., as president of research and development. Under Erasca’s 2026 Employment Inducement Incentive Award Plan, Dr. Fuchs received non-qualified stock options to purchase 1,278,520 shares of common stock.
According to Erasca, the options were granted on August 10, 2026 at an exercise price equal to the closing price of Erasca common stock on the Nasdaq Global Select Market that day. Twenty-five percent of the options will vest on August 10, 2027, with the remainder vesting in 36 equal monthly installments thereafter, consistent with Nasdaq Listing Rule 5635(c)(4) for inducement grants.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Explained
The appointment-linked award does not issue the 1,278,520 shares immediately; it gives Dr. Fuchs options to purchase them, creating potential future dilution for existing common holders if the options vest and are exercised.
Market Context
ERAS’s active S-3ASR, filed July 13, 2026, supplies platform context for this leadership appointment...
Analysis
ERAS’s active S-3ASR, filed July 13, 2026, supplies platform context for this leadership appointment and inducement award. The main watchpoint is capital-structure dilution alongside the absence of a reported operating result.
Key Figures
Inducement stock options:1,278,520 sharesInitial vesting:25%Remaining vesting:36 equal monthly installments+2 more
5 metrics
Inducement stock options1,278,520 sharesGrant to the president of research and development
Initial vesting25%Vests on August 10, 2027
Remaining vesting36 equal monthly installmentsAfter the initial 25% vesting
Grant dateAugust 10, 2026Stock options granted on the announcement date
Nasdaq listing rule5635(c)(4)Rule cited for employment inducement awards
"focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers"
A cellular signaling route that acts like a chain of command inside cells to tell them when to grow, divide, or die; when parts of this RAS/MAPK pathway are stuck “on,” it can drive uncontrolled cell growth that leads to cancer. Investors care because drugs, tests, or diagnostics that target or measure this pathway can become valuable products, affect drug approval chances, and change a company’s revenue or risk profile much like fixing a critical production line in a factory.
non-qualified stock optionsfinancial
"grant to Dr. Fuchs of non-qualified stock options to purchase 1,278,520 shares"
Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.
nasdaq listing rule 5635(c)(4)regulatory
"pursuant to Nasdaq Listing Rule 5635(c)(4)"
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
SAN DIEGO, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that, in connection with the appointment of Charles S. Fuchs, M.D., M.P.H., as president of research and development, Erasca’s Board of Directors has approved the grant of inducement awards.
The Board of Directors approved the grant to Dr. Fuchs of non-qualified stock options to purchase 1,278,520 shares of Erasca common stock under the company’s 2026 Employment Inducement Incentive Award Plan (the “Inducement Plan”), 25% of which will vest on August 10, 2027, and the remainder of which will vest in 36 equal monthly installments thereafter.The stock options were granted on August 10, 2026 with an exercise price equal to the closing price of Erasca’s common stock on the Nasdaq Global Select Market on the grant date.
The Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Erasca, or following a bona fide period of non-employment, as an inducement material to such individuals’ entering into employment with Erasca, pursuant to Nasdaq Listing Rule 5635(c)(4).
About Erasca At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of patients with cancer. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.
What inducement stock option grant did Erasca (ERAS) give Charles S. Fuchs on August 10, 2026?
Erasca granted Charles S. Fuchs non-qualified stock options to purchase 1,278,520 shares of common stock. According to Erasca, these options were issued under the 2026 Employment Inducement Incentive Award Plan in connection with his appointment as president of research and development, following Nasdaq Listing Rule 5635(c)(4).
What is the vesting schedule for Charles S. Fuchs’ Erasca (ERAS) inducement stock options?
The inducement stock options vest over four years. According to Erasca, 25% of the options will vest on August 10, 2027, with the remaining 75% vesting in 36 equal monthly installments thereafter, provided that the applicable continued service conditions are satisfied.
How is the exercise price determined for the Erasca (ERAS) inducement options granted on August 10, 2026?
The exercise price equals the market close on the grant date. According to Erasca, the non-qualified stock options granted on August 10, 2026 have an exercise price set at the closing price of Erasca’s common stock on the Nasdaq Global Select Market on that same date.
What is Erasca’s 2026 Employment Inducement Incentive Award Plan and who can receive awards?
The 2026 Employment Inducement Incentive Award Plan is used solely for hiring-related equity grants. According to Erasca, it is reserved for individuals who were not previously employees, or after a bona fide break in service, as a material inducement for entering into employment with the company under Nasdaq Rule 5635(c)(4).
Why does Erasca (ERAS) use Nasdaq Listing Rule 5635(c)(4) for these inducement grants?
Erasca uses Nasdaq Listing Rule 5635(c)(4) to grant equity as an employment inducement without prior shareholder approval. According to Erasca, the Inducement Plan is exclusively for such awards to new or returning employees, aligning the company’s hiring practices with Nasdaq’s specific inducement grant framework.
